
Scottish graduates first to qualify as doctors through part-time study
It is open exclusively to existing healthcare professionals, clinical scientists and veterinary surgeons living and working in Scotland.
The course has been designed to address the increasing demand on the healthcare workforce in Scotland and has a strong emphasis on GP placements.
READ MORE: Lap dancing club loses appeal with council over sign
The first three years of the undergraduate course are conducted part-time and mainly online, so that students can study in their own time while balancing work and other commitments.
After completing their remote studies, students then join the university's full-time undergraduate medical programme for the final two years and carry out a range of clinical placements in GP practice and hospital wards.
Dr Jen Kennedy, programme director HCP-MED, said: 'We have lots of incredibly talented people working within the NHS in Scotland who may have missed the traditional route to become doctors.
'By creating this new pathway and widening access to medical degrees, we are able to nurture their talent and use their valuable experience to enhance the healthcare workforce.'
Calum MacDonald, who started his career as a staff nurse in an intensive care unit in Glasgow, is part of the first cohort of students who graduated from the programme on Saturday.
(Image: Douglas Robertson/University of Edinburgh/PA Wire) His experience working in intensive care and subsequent training to become an advanced critical care practitioner, a role he has held since 2016, led him to consider a career as a doctor.
He became a father in his second year of the course and the programme enabled him to stay in Glasgow and balance work with part time study and family life.
Now a newly qualified doctor, he has secured a foundation post in Glasgow and will rotate across seven specialties.
He said: 'I'm very proud to fly the flag for the HCP-Med programme – it's been a challenging but incredibly rewarding journey.
'Being able to continue working as a nurse while studying medicine was a huge financial incentive.
I am delighted to be graduating today and am excited to start my placement as a junior doctor in Glasgow.'
READ MORE: Search launched for 15-year-old girl missing from Stonehaven
He is considering specialising in anaesthetics or general practice.
Alongside the part-time study, students receive full funding from the Scottish Funding Council which the university said makes it an attractive route to retrain for those already working within the healthcare industry.
Professor David Kluth, head of Edinburgh Medical School, said: 'I am very proud that Edinburgh is the first university in the UK to offer this innovative part-time programme.
'We are committed to doing all we can to empower individuals to reach their full potential and to widen access to medicine for future generations.
'The students on this programme bring with them a rich diversity of backgrounds, experiences and skills – from prior careers to lived experience of the communities they will serve.
'This breadth of talent and perspective is vital in building a more inclusive, adaptable, and effective medical workforce for Scotland.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

South Wales Argus
2 hours ago
- South Wales Argus
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

Rhyl Journal
2 hours ago
- Rhyl Journal
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'

Leader Live
2 hours ago
- Leader Live
Weight-loss jabs could help obese people control asthma, study suggests
The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'